COMPARISON
EvidenceFlow vs Rayyan for Systematic Reviews
Last reviewed September 14, 2026
Rayyan.ai is one of the most widely used tools for systematic review screening, with a large free tier and a well-regarded blind dual-review mode. The main difference is scope: Rayyan covers screening, deduplication, basic data extraction, risk-of-bias assessment, and PRISMA diagrams, but does not perform statistical meta-analysis itself - reviews that need pooled effect sizes typically export their data to a separate tool like RevMan or an R package. EvidenceFlow covers the same screening and PRISMA ground and continues through to built-in meta-analysis, so the same dataset that was screened is the one that gets pooled.
Feature comparison
| Feature | EvidenceFlow | Rayyan |
|---|---|---|
| Title/abstract & full-text screening | Yes | Yes |
| Blind dual-reviewer screening | Yes, configurable reviewer count per stage | Yes ("Blind Mode"), on by default, owner-controlled |
| Conflict resolution workflow | Third reviewer, review manager, or consensus | Manual review with Blind Mode turned off |
| Automatic deduplication | Yes, on import | Yes, incl. auto-resolver for near-duplicates |
| Structured data extraction | Yes, incl. clinical + omics fields, AI auto-fill (paid) | Yes, custom extraction fields; AI-assisted PICO extraction (paid plans) |
| Risk-of-bias assessment | Basic fields in extraction (randomization, blinding, attrition, overall judgment) - not a structured domain-by-domain tool | Yes, built in (Cochrane RoB tool by default, customizable) |
| PRISMA 2020 flow diagram | Yes, generated automatically from screening data | Yes, generated in the reporting stage |
| Built-in meta-analysis (pooled effects, forest/funnel plots) | Yes - fixed/random effects, Mantel-Haenszel, Peto | No - export to a separate tool (e.g. RevMan, R) for pooling |
| AI relevance scoring for screening | Optional, paid upgrade | Yes ("ResearchPilot"), varies by plan |
| Free-tier review limit | No limit on number of reviews | 3 active reviews on the free plan |
Source for Rayyan's column: www.rayyan.ai/
Who each tool fits best
Consider EvidenceFlow if
- You want screening, extraction, PRISMA reporting, and meta-analysis in one connected workspace, without exporting data between tools.
- You're running more than a couple of reviews at once and don't want a review-count cap on the free tier.
- Your review includes genomics/omics data alongside clinical outcomes.
Consider Rayyan if
- You specifically need a dedicated risk-of-bias assessment module.
- Your team is already invested in Rayyan's mobile app for screening on the go.
- You only need screening and PRISMA reporting, and already have a separate meta-analysis workflow (e.g. RevMan or R) you're happy with.
Feature availability, limits, and pricing vary by plan and can change - this is a starting point for your own evaluation, not a substitute for it.
Workflow comparison
Both tools take you from imported references through blinded dual screening to a PRISMA 2020 diagram. The workflows diverge after eligibility: in Rayyan, included studies and any extracted data are typically exported for statistical analysis elsewhere. In EvidenceFlow, the same included studies flow directly into data extraction and then into the built-in meta-analysis engine - import → screening → dual review → extraction → PRISMA → analysis → export happens without leaving the platform or re-entering data into a second tool.
Pricing
EvidenceFlow
Free: import, screening, extraction, meta-analysis, and PRISMA reporting - no review limit, no seat limit.
₹399/month: adds AI-assisted screening suggestions, extraction auto-fill, and AI manuscript drafting.
Rayyan
Free: 3 active reviews, 2 collaborators.
Essential: from $4.99/seat/month (billed annually) or $8.33/month (quarterly) - 9 active reviews, 5 collaborators, PRISMA diagrams.
Advanced: from $8.33/seat/month (annual) - adds AI-assisted PICO extraction.
Business/Enterprise: from $41.67/license/month (5-license minimum) - org-wide reviews, SSO on Enterprise.
Rayyan pricing source: www.rayyan.ai/pricing (checked September 14, 2026). Confirm current pricing directly with Rayyan before deciding.
FAQ
Is EvidenceFlow an alternative to Rayyan?
For screening and PRISMA reporting, yes - the core workflow is comparable. EvidenceFlow additionally includes built-in meta-analysis, which Rayyan does not offer; Rayyan includes a dedicated risk-of-bias module, which EvidenceFlow does not.
Does EvidenceFlow support blind dual review like Rayyan's Blind Mode?
Yes. You can configure how many independent reviewers are required at each screening stage and how conflicts get resolved (third reviewer, review manager, or consensus).
Can I do a full meta-analysis without leaving EvidenceFlow?
Yes - fixed and random-effects models, Mantel-Haenszel and Peto pooling, and forest/funnel plots are built in, using the same data your team extracted during screening.
Which tool should a review team choose?
If your review needs pooled statistical results and you'd rather not hand off data to a second tool, EvidenceFlow's built-in meta-analysis is the more direct path. If you specifically need Rayyan's risk-of-bias module or its mobile screening app, and you already have a meta-analysis workflow you're happy with, Rayyan may fit better. Feature sets on both platforms change - check each provider's current documentation before deciding.
Core import, screening, extraction, meta-analysis, and PRISMA reporting are free with no subscription or seat limits. AI-assisted screening, extraction auto-fill, and manuscript drafting are an optional paid upgrade.